Apogee Therapeutics, Inc. (APGE)
After hours:
- GlobeNewswire
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr.
- GuruFocus.com
Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)
The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 280,793 shares of Apogee Therapeutics Inc. Apogee Therapeutics Inc (NASDAQ:APGE) is a biopharmaceutical company focused on the development and commercialization of novel therapies to treat autoimmune and inflammatory diseases.
- GuruFocus.com
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
The transaction was documented in an SEC Filing. Following this sale, the insider now owns 200,871 shares of Apogee Therapeutics Inc. Apogee Therapeutics Inc is engaged in the development and commercialization of various therapies aimed at treating diseases with significant unmet medical needs.
